Cellebrite DI Ltd. (CLBT): one to watch?
Interesting but unresolved — a guidance cut plus abrupt CEO change and a shareholder-lawsuit probe make it too early to call this a bargain.
Fell 29% in 8 trading day(s) — now $11.31
Why CLBT dropped
Cellebrite crashed after missing Q2 revenue, cutting full-year revenue/ARR guidance due to delayed government contract closings, and abruptly naming a new CEO — all on the same day.
Fwd P/E 17.3Op margin 5.3%Rev growth 15.8%Debt/equity 4.3%Analyst upside 35.8%
How this scored 57/100
✅ Passes all 4 hard checks — profitable, cash-generative, and financially survivable.
Makes money
Net profit margin 11.4%
Generates cash
Free cash flow $125M
Not drowning in debt
Debt/equity 4.3% (limit 200%)
Can pay its bills
Current ratio 1.6 (needs 1+)
Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.
Profitability
Does it actually make money?
9/25
Operating margin
5.3%
2/9
Net profit margin
11.4%
5/8
Return on equity
12.4%
3/8
Growth
Is it getting bigger, or dying?
14/25
Revenue growth
15.8%
6/9
Earnings growth
-67.9%
0/8
Expected profit change
184.0%
8/8
Value
Is it cheap right now?
14/25
Forward P/E
17.3
7/10
PEG ratio
unknown
2/8
Analyst target upside
35.8%
4/7
Balance sheet
Will it survive?
20/25
Debt / equity
4.3%
10/10
Current ratio
1.6
3/8
Free cash flow
$125M
7/7
🔒 Read the full AI analysis
Create a free account to unlock the bull case and the risks for CLBT — plus today's other picks.
Analysis generated by SmartStonks's AI from public fundamentals and news, first flagged 2026-08-21. Research only — not financial advice.